Compare Citius Pharmaceuticals Inc (CTXR) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Star Bulk Carriers Corp trades at $29.94 (market cap $3.54B). The key difference: Star Bulk Carriers Corp is far larger — about 259.9× Citius Pharmaceuticals Inc's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Star Bulk Carriers Corp for 24 Days on average.
| CTXR | SBLK | |
|---|---|---|
Market Cap | $13.62M | $3.54B |
Volume | 132,438 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $1.82 | $32.49 |
52-Week Low | $0.48 | $16.79 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.79M | $4.22B |
Dividend Yield | — | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Star Bulk Carriers (SBLK) trades at $29.86, up 0.57% today, with a bullish technical signal from moving averages and a neutral RSI. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and a net income margin of 23.87%. Recent news highlights insider buying and a declared $0.90 dividend, reflecting confidence in the shipping sector's momentum.
The outlook for SBLK is positive, supported by robust earnings growth, attractive valuation metrics like a P/E of 11.95, and a high analyst buy consensus of 58.34%. Key risks include exposure to volatile shipping rates and macroeconomic pressures, but the company's solid cash flow and dividend policy offer shareholder value. Upside potential hinges on continued operational execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
